ea0025p18 | Bone | SFEBES2011
Eastell Richard
, Reid Ian
, Cauley Jane
, Boonen Steven
, Cosman Felicia
, Leung Ping Chung
, Lakatos Peter
, Man Zulema
, Cummings Steven
, Hue Trisha
, Ruzycky MaryEllen
, Martinez Ruvie
, Su Guoqin
, Bucci-Rechtweg Christina
, Black Dennis
Treatment with a single annual infusion of zoledronic acid 5 mg (ZOL) for 3 years has been shown to be effective in increasing bone mineral density (BMD) and decreasing fractures. In order to investigate the long-term effects of ZOL, we performed a 3-year extension of the HORIZON-PFT to 6 years. A total of 1233 women who received ZOL for 3 years in the core study were randomly allocated to 3 additional years of ZOL (Z6, n=616) or blinded placebo (Z3P3, n=617). Pr...